PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer.
PI3Kinase inhibitor
breast cancer
hormone receptor positive breast cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
02 Nov 2021
02 Nov 2021
Historique:
received:
21
09
2021
revised:
27
10
2021
accepted:
29
10
2021
entrez:
13
11
2021
pubmed:
14
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Derangement of the phosphatidylinositol-3 kinase (PI3K) pathway is implicated in several subtypes of breast cancers. Mutation or upregulation of PI3K enhances cancer cells' survival, proliferation, and ability to metastasize, making it an attractive molecular target for systemic therapy. PI3K has four isoforms, and several drugs targeting individual isoforms or pan-PI3K have been or are currently being investigated in clinical trials. However, the search for an effective PI3K inhibitor with a robust therapeutic effect and reasonable safety profile for breast cancer treatment remains elusive. This review focuses on the recently completed and ongoing clinical trials involving PI3K inhibitors as mono- or combination therapy in breast cancer. We review the salient findings of clinical trials, the therapeutic efficacy of PI3K inhibitors, and reported adverse effects leading to treatment discontinuation. Lastly, we discuss the challenges and potential opportunities associated with adopting PI3K inhibitors in the clinic.
Identifiants
pubmed: 34769309
pii: ijms222111878
doi: 10.3390/ijms222111878
pmc: PMC8584833
pii:
doi:
Substances chimiques
Phosphoinositide-3 Kinase Inhibitors
0
Receptors, Estrogen
0
Receptors, Progesterone
0
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001413
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001412
Pays : United States
Références
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
Cancer Discov. 2021 Jan;11(1):92-107
pubmed: 32958578
Clin Cancer Res. 2018 Sep 15;24(18):4380-4387
pubmed: 29793946
Ann Oncol. 2017 Feb 1;28(2):313-320
pubmed: 27803006
Clin Cancer Res. 2017 Jan 1;23(1):26-34
pubmed: 27126994
Clin Cancer Res. 2021 Apr 1;27(7):1842-1849
pubmed: 33168657
Breast Cancer Res. 2020 Nov 2;22(1):120
pubmed: 33138866
Mol Cancer Ther. 2014 May;13(5):1117-29
pubmed: 24608574
Lancet Oncol. 2019 Sep;20(9):1226-1238
pubmed: 31402321
Nat Rev Genet. 2006 Aug;7(8):606-19
pubmed: 16847462
J Clin Oncol. 2004 Jul 15;22(14):2954-63
pubmed: 15254063
Ann Oncol. 2020 Mar;31(3):377-386
pubmed: 32067679
Nat Rev Cancer. 2015 Jan;15(1):7-24
pubmed: 25533673
Cancer Sci. 2014 Mar;105(3):347-53
pubmed: 24405565
Clin Cancer Res. 2021 Jan 15;27(2):447-459
pubmed: 33148674
Cancer Res. 2009 May 1;69(9):3955-62
pubmed: 19366795
Cancer Res. 2005 Dec 1;65(23):10992-1000
pubmed: 16322248
Nat Rev Cancer. 2002 Jul;2(7):489-501
pubmed: 12094235
JAMA Oncol. 2019 Feb 1;5(2):e184475
pubmed: 30543347
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
Breast Cancer Res Treat. 2018 Sep;171(2):371-381
pubmed: 29850984
J Clin Oncol. 2014 Apr 20;32(12):1202-9
pubmed: 24663045
Ann Oncol. 2021 Feb;32(2):197-207
pubmed: 33186740
Science. 2002 May 31;296(5573):1655-7
pubmed: 12040186
Breast Cancer Res. 2011 Mar 01;13(2):R21
pubmed: 21362200
J Clin Oncol. 2012 Jan 20;30(3):282-90
pubmed: 22162589
J Med Chem. 2016 Feb 11;59(3):985-1002
pubmed: 26741947
Clin Cancer Res. 2021 Jan 15;27(2):408-417
pubmed: 32718997
Cancer Res. 2008 Aug 1;68(15):6084-91
pubmed: 18676830
Lancet Oncol. 2021 Apr;22(4):489-498
pubmed: 33794206
Lancet Oncol. 2017 Jul;18(7):904-916
pubmed: 28576675
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18443-8
pubmed: 16339315
Invest New Drugs. 2014 Aug;32(4):670-81
pubmed: 24652201
Clin Cancer Res. 2020 May 1;26(9):2111-2123
pubmed: 31822498
Breast Cancer Res Treat. 2008 Nov;112(2):217-27
pubmed: 18074223
Sci Transl Med. 2015 Apr 15;7(283):283ra51
pubmed: 25877889
J Med Chem. 2013 Jun 13;56(11):4597-610
pubmed: 23662903
Genes Cancer. 2016 Mar;7(3-4):73-85
pubmed: 27382432
ACS Med Chem Lett. 2011 Aug 26;2(10):774-9
pubmed: 24900266
JCO Precis Oncol. 2020 May 27;4:
pubmed: 32923889
Lancet Oncol. 2018 Jan;19(1):87-100
pubmed: 29223745
Clin Cancer Res. 2021 Jan 15;27(2):418-428
pubmed: 32887722
Curr Opin Cell Biol. 1999 Apr;11(2):219-25
pubmed: 10209156
Eur J Cancer. 2017 Nov;85:133-145
pubmed: 28923573